Levocarb-Gry (Levodopa, Carbidopa Monohydrate)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, restoring depleted central dopamine levels. Carbidopa inhibits the peripheral enzyme aromatic L‑amino acid decarboxylase, preventing levodopa from being converted outside the brain and thereby increasing its central availability while reducing peripheral side effects.

The specific dose of Levocarb-Gry is individualized by the prescribing clinician based on the patient’s disease severity, response, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing adverse effects.

Safety data for levodopa/carbidopa in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the Levocarb-Gry product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levocarb-Gry combines levodopa with carbidopa, offering a higher proportion of levodopa to reach the brain compared with levodopa alone. Compared with dopamine agonists, it typically provides stronger symptomatic relief but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and treatment goals.

Levocarb-Gry should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Levocarb-Gry is taken orally, usually with a glass of water. It can be taken with or without food, but high‑protein meals may interfere with absorption, so spacing the dose from protein‑rich meals is often recommended. The prescribing clinician will provide specific timing instructions.

Serious risks include the development of dyskinesia (involuntary movements), hallucinations or psychotic episodes, severe hypotension, and rare allergic reactions such as rash or angioedema. Patients should be monitored regularly for these events, and any sudden changes in mental status or movement should be reported promptly.

Levocarb-Gry is contraindicated in patients with known hypersensitivity to levodopa, carbidopa, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma, as it may exacerbate intra‑ocular pressure.